How to Reduce Your PMDA Submission Timeline by 6 Months

Japan PMDA approval timelines have a reputation for being long. And while it's true that Class III device approvals can take 18–24 months, a significant portion of that time is often avoidable delay — caused by preventable mistakes, incomplete submissions, and missed optimization opportunities.

In this article, we share five practical strategies that experienced regulatory consultants use to compress the Japan approval timeline — often by 6 months or more.

Why Timelines Slip: The Most Common Causes

Before discussing solutions, it's worth understanding where time is typically lost:

Delay Source	Typical Impact
Incomplete submission package	3–6 months (additional information requests)
Incorrect device classification	6–12 months (reclassification and resubmission)
Poor clinical evidence strategy	6–18 months (additional clinical data required)
PMDA pre-submission consultation skipped	3–6 months (avoidable surprises during review)
Translation quality issues	1–3 months (clarification requests)

Strategy 1: Use PMDA Pre-Submission Consultation (事前面談)

PMDA offers pre-submission consultation meetings (事前面談, jizen mendan) where you can discuss your device, proposed submission strategy, and clinical evidence approach with PMDA reviewers before filing.

Why this saves time: PMDA reviewers will flag potential issues with your strategy before you invest months preparing documents. A single consultation can prevent a 6-month delay caused by an avoidable clinical data gap.

Best practice: Schedule the consultation 6–9 months before your planned submission date. Prepare a concise device overview and your proposed clinical evidence strategy.

Strategy 2: Choose the Right Submission Route from the Start

As discussed in our device classification article, the classification determines your submission route:

• Class II via RCB (Registered Certification Body): 6–12 months
• Class III via PMDA direct review: 12–24 months

If your device can legitimately be classified as Class II, the RCB route is significantly faster. Misclassifying a Class II device as Class III — or vice versa — wastes months.

Best practice: Conduct a thorough classification analysis early, and confirm with PMDA if there's any ambiguity.

Strategy 3: Invest in Clinical Evidence Strategy Early

The most common cause of PMDA additional information requests (AIRs) is insufficient clinical evidence. This is also the most time-consuming delay to recover from.

The clinical evaluation approach — using existing clinical literature rather than new clinical trials — is the fastest path for most devices. But it requires:

• A well-structured Clinical Evaluation Plan (CEP) aligned with PMDA expectations
• Comprehensive literature search with documented methodology
• Rigorous critical appraisal of included studies
• Clear benefit-risk argumentation

Best practice: Start the clinical evidence strategy 12+ months before your target submission date. Don't wait until the STED is nearly complete to think about clinical data.

Strategy 4: Prepare a Complete, High-Quality Submission Package

PMDA reviewers issue Additional Information Requests (AIRs) when submissions are incomplete or unclear. Each AIR adds 2–4 months to the timeline.

Common AIR triggers:

• Missing or incomplete non-clinical test reports
• Unclear device description or intended use
• Insufficient biocompatibility data
• Incomplete manufacturing quality documentation

Best practice: Use a pre-submission checklist aligned with PMDA's review standards. Have an experienced regulatory consultant review the package before filing.

Strategy 5: Leverage Existing Overseas Approval Data

If your device already has FDA 510(k) clearance or CE marking, this data can significantly reduce the clinical evidence burden for PMDA:

• FDA clinical data can be referenced in the CER (with appropriate bridging argumentation)
• CE marking demonstrates conformity with international standards recognized by PMDA
• ISO 13485 certification streamlines quality system documentation

Best practice: Map your existing regulatory data to PMDA requirements early. Identify gaps and address them proactively rather than reactively.

Realistic Timeline Expectations

With all strategies implemented:

Device Type	Optimized Timeline
Class II (RCB certification)	6–9 months
Class III (PMDA approval, clinical eval)	12–18 months
Class III (PMDA approval, new clinical trial)	24–36 months

How MK Consulting Can Help

At MK Consulting, we specialize in optimizing PMDA submission timelines for GI endoscopy and other medical devices. Our approach:

1. Early strategy consultation: We identify the fastest compliant submission route for your device
2. PMDA pre-submission consultation support: We prepare and accompany you to PMDA meetings
3. Clinical evidence strategy: We design a CER approach that meets PMDA standards without unnecessary clinical trials
4. Complete submission package preparation: We prepare all documents to minimize AIR risk

Contact us for a free timeline assessment →